First quarter financial year core operating profit for Tokyo-based Astellas Pharma reached ¥67.1 billion, up a tad more than 49% even as overall sales dipped on reimbursement price revisions in Japan.
However, the company said in a release that sales of Xtandi (enzalutamide) grew and aided the bottom line along with the transfer of the global dermatology business in April, part of a $727 million deal with Danish specialty product firm LEO last year.
"We are pleased with our solid performance and ability to achieve sustainable growth through increasing sales of Xtandi … and overall (bladder) treatments, new product introductions and focused investment in innovation and strengthening our base,” said Yoshihiko Hatanaka, president and CEO of Astellas.
Overall sales, however, fell nearly 6% in the first quarter ended June 30, compared to the same period a year ago, to ¥337.8 billion.
- here's the release
British watchdogs suspend Astellas UK after investigations, audits, and a crackdown from Japanese HQ
Drug price cuts in Japan sink in though details sparse
Japan's Astellas eyed to buy Kaketsuken's vaccine business
Astellas' Xtandi under pressure as U.S. lawmakers push for generic swap
Japan's Astellas Pharma gets $727M for ailing dermatology unit as it swings to new areas